Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Features

Reimbursement Issues Seem to Be Holding Renal Denervation Back

Todd Neale

December 19, 2024

Presentation TCT 2024

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

Presenter: Daria Feshchenko

October 28, 2024

Presentation TCT 2024

TCT 1280: Extravascular Renal Denervation in Patients With Resistant Hypertension: Challenging Experience From the First-in-Human Trial in Korea

Presenter: Chang Wook Jeong

October 28, 2024

News Conference News ESC 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Yael L. Maxwell

September 04, 2024

Presentation ESC 2024

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Presenter: Stefano Taddei

August 31, 2024

News Conference News ESC 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

L.A. McKeown

August 31, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

News Daily News

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

Michael O'Riordan

February 07, 2024

Presentation

RDN to treat Resistant Hypertension

Presenter: Tai Kobayashi

November 10, 2023

Advertisement

Reimbursement Issues Seem to Be Holding Renal Denervation Back

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

TCT 1280: Extravascular Renal Denervation in Patients With Resistant Hypertension: Challenging Experience From the First-in-Human Trial in Korea

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Polypills Show Promise in Diverse Hypertensive Patient Groups

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Evoque and Patisiran: A Tale of Two Regulatory Journeys

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

RDN to treat Resistant Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content